Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Niclosamide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 16Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ADM Korea Targets Prostate Cancer For Niclosamide-Based Drug Trial
    ADM Korea Targets Prostate Cancer For Niclosamide-Based Drug Trial

    11 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/adm-korea-announces-niclosamide-based-metabolic-anticancer-drugs-first-clinical-trial-target-as-prostate-cancer-patients-resistant-to-hormone-therapy-302194534.html

    PR NEWSWIRE
    11 Jul 2024
    Share Share
    Korean firm Hyundai Bioscience soon to initiate global clinical development
    Korean firm Hyundai Bioscience soon to initiate global clinical development

    22 Apr 2024

    // BIOSPECTRUM ASIA

    https://www.biospectrumasia.com/news/25/24109/korean-firm-hyundai-bioscience-soon-to-initiate-global-clinical-development-on-dengue-antiviral-candidate.html

    BIOSPECTRUM ASIA
    22 Apr 2024
    Share Share
    First Wave BioPharma Files U.S. and PCT Patent Applications for Niclosamide
    First Wave BioPharma Files U.S. and PCT Patent Applications for Niclosamide

    28 Mar 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/03/28/2411405/0/en/First-Wave-BioPharma-Files-U-S-and-PCT-Patent-Applications-for-Niclosamide-in-Long-Haul-COVID-19.html

    GLOBENEWSWIRE
    28 Mar 2022
    Share Share
    TFF Reports Inhaled Niclosamide Inhibits Viral Replication of Omicron Variant
    TFF Reports Inhaled Niclosamide Inhibits Viral Replication of Omicron Variant

    24 Feb 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/02/24/2391586/0/en/TFF-Pharmaceuticals-Announces-Inhaled-Niclosamide-Significantly-Inhibits-Viral-Replication-of-the-Omicron-Variant-of-SARS-CoV-2.html

    GLOBENEWSWIRE
    24 Feb 2022
    Share Share
    TFF Pharma Completes Enrollment in Phase 1 Evaluating Niclosamide for COVID-19
    TFF Pharma Completes Enrollment in Phase 1 Evaluating Niclosamide for COVID-19

    27 Jan 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/01/27/2374302/0/en/TFF-Pharmaceuticals-Completes-Enrollment-in-Phase-1-Study-Evaluating-Inhaled-Formulation-of-Niclosamide-to-Treat-COVID-19.html

    GLOBENEWSWIRE
    27 Jan 2022
    Share Share
    UNION therapeutics announces enrollment of first patient in the PREVENT study
    UNION therapeutics announces enrollment of first patient in the PREVENT study

    22 Oct 2021

    // CISION

    https://news.cision.com/union-therapeutics/r/union-therapeutics-announces-enrollment-of-first-patient-in-the-prevent-study-evaluating-niclosamide,c3438458

    CISION
    22 Oct 2021
    Share Share